Medication Exposure in Older Patients With Constitutional Hemorrhagic Disease

NCT04282486 | Completed

• 1 other identifier: 69HCL20_0086
• Study Type: observational
• Target: 142
• Locations: 1 country
• Sites: 1

Brief Summary

The improvements observed in the care of patients with hemophilia or Willebrand disease have led to an increase in their life expectancy, which today approaches that of the general population. This increase in life expectancy leads in these patients to the development of comorbidities related to aging (cardiovascular and neurological diseases, cancers and kidney diseases) (e.g "Franchini \& Mannuccio", BJH, 2009). The care of these comorbidities represents a new challenge for the medical teams. Toward multiple comorbidities, polypharmacy is often associated. Many studies about medication exposure and management in older patients were published but no study was conducted to explore the medication management of older patients with hemophilia or Willebrand disease.

Conditions

Hemophilia

Keywords

Willebrand disease

Outcome Measures

Primary Outcomes (1)

• Potentially inappropriate medication (PIM) prevalence using EU-(7) PIM list.

  A telephone interview will be conducted with patients in order to collect medication data from medical prescriptions. After collection of data for all patients, the research of PIM was conducted.

  At inclusion

Interventions

Telephone interview OTHER

Primary objective: potentially inappropriate medication prevalence Secondary objective: Number and type of medication Polypharmacy prevalence Medication regimen complexity using Medication Regimen Complexity Index Anticholinergic and sedative exposure using Drug Burden Index A telephone interview will be conducted with patients in order to collect medication data from medical prescriptions.

Eligibility Criteria

• Age: Up to 65 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Child (0-17), Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Elderly patients with hemophilia or Willebrand's disease (over 65) will have a telephone interview in order to collect medication data from medical prescriptions.

You may qualify if:

• Community-dwelling patients over 65 years with hemophilia (A or B)
• Community-dwelling patients over 65 years with Willebrand disease (Type1, 2 and 3, rate \<30%)

You may not qualify if:

• Patients without phone number
• Non French speaking patients

Sponsors & Collaborators

• Hospices Civils de Lyon: lead

Study Sites (1)

Hôpital des Charpennes, Institut du Vieillissement

Villeurbanne, 69100, France

Location

MeSH Terms

Conditions

Hemophilia A

Interventions

Interviews as Topic

Condition Hierarchy (Ancestors)

Blood Coagulation Disorders, Inherited; Blood Coagulation Disorders; Hematologic Diseases; Hemic and Lymphatic Diseases; Coagulation Protein Disorders; Hemorrhagic Disorders; Genetic Diseases, Inborn; Congenital, Hereditary, and Neonatal Diseases and Abnormalities

Intervention Hierarchy (Ancestors)

Data Collection; Epidemiologic Methods; Investigative Techniques; Health Care Evaluation Mechanisms; Quality of Health Care; Health Care Quality, Access, and Evaluation; Public Health; Environment and Public Health

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: CROSS SECTIONAL
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: February 21, 2020
• First Posted: February 24, 2020
• Study Start: July 22, 2020
• Primary Completion: January 29, 2021
• Study Completion: January 29, 2021
• Last Updated: July 13, 2021

Record last verified: 2021-07

Locations

FR (1)